- 3SBio Inc.
- Algeta ASA
- Molecular Insight Pharmaceuticals Inc.
- Merck KGaA
- Shire PLC
- New River Pharmaceuticals Inc.
- Movetis NV
- Johnson & Johnson
- Zogenix Inc.
- Organon NV
- Akzo Nobel NV
- Schering-Plough Corp.
- Tanabe Seiyaku Co. Ltd.
- Mitsubishi Chemical Holdings Corp.
- Mitsubishi Tanabe Pharma Corp.
- Eisai Co. Ltd.
- Morphotek Inc.
- Eli Lilly & Co.
- Hypnion Inc.
- AstraZeneca PLC
- Arrow Therapeutics Ltd.
- Oxford BioMedica PLC
- GlaxoSmithKline PLC
- XenoPort Inc.
- Genmab AS
- Accuray Inc.
- Boston Scientific Corp.
- Kyphon Inc.
- DaVita HealthCare Partners Inc.
- BioTelemetry Inc.
- Molnlycke Health Care AB
- Eastman Kodak Co.
- Carestream Health Inc.
- Abbott Medical Optics Inc.
- IntraLase Corp.
- WaveFront Sciences Inc.
- Smith & Nephew PLC
- Plus Orthopedics AG
- Rosetta Genomics Ltd.
- Illumina Inc.
- Alere Inc.
- First Check Diagnostics LLC
- Instant Technologies Inc.
- Claros Diagnostics Inc.
- Cognoptix Inc.
- Prognomix Inc.
- GE Healthcare
- General Electric Co.
- Abbott Laboratories Inc.
- Abbott Point of Care
- Abbott Diagnostics
- Dako AS
- Novo Nordisk AS
- Beckman Coulter Inc.
- Biosite Inc.
- Quest Diagnostics Inc.
- HemoCue AB
- CuraGen Corp.
- 454 Life Sciences
- China's 3SBio closes $107mm IPO
- Algeta completes NOK250mm IPO
- Molecular Insight completes $65.1mm IPO
- Merck KGAA grosses €1bn through capital increase
- Merck KGAA to buy Serono for CHF16.6bn
- PIPE brings in $900mm for Shire
- Shire buys New River for $2.6bn
- Series A raises €49mm for Movetis NV
- Start-up Zogenix grosses $60mm with Series A; adds $18mm
- Movetis gets rights to some J&J compounds
- Akzo Nobel scraps plan to divest Organon through IPO
- Schering-Plough buys Organon for €11bn in cash
- Shire licenses New River's ADHD candidate
- Tanabe Seiyaku to merge with Mitsubishi
- Eisai to acquire US biotech Morphotek for $325mm
- Eli Lilly buys sleep therapy company Hypnion for $315mm
- AstraZeneca buys Arrow Therapeutics for $150mm
- AZ and BMS enter Type II diabetes deal; BMS later sells diabetes business to AZ
- Sanofi gets rights to Oxford BioMedica's TroVax; ended
- GSK and XenoPort join forces on restless leg/pain agent; terminated
- GSK gets late-stage cancer/RA antibody from Genmab; transferred to Novartis
- Accuray completes $174mm IPO
- Kyphon sells $400mm in convertible senior notes
- DaVita gets $400mm with private sale of notes
- Kyphon acquires St. Francis for $525mm in cash plus earn-outs
- CardioNet gets $110mm with equity bridge financing
- Two investor groups buy Molnlycke for €2.85bn
- Eastman Kodak sells off its health imaging group
- AMO to offer all-laser Lasik after $808mm IntraLase buy
- AMO acquires WaveFront Sciences for $14mm plus earn-outs
- Smith & Nephew pays $899mm for Plus Orthopedics
- Rosetta Genomics nets $26.2mm through IPO on Nasdaq
- Illumina buys Solexa in stock-for-stock transaction
- Illumina nets $390mm in placement of convertible debt
- Inverness Medical Innovations nets $261.3mm with FOPO
- Inverness gains OTC diagnostics via $25mm First Check buy
- IMI buys 75% of Instant Technologies for $44mm in cash/stock
- Claros Diagnostics gets $7.8mm in Series A round
- Alzheimer's diagnosis company Neuroptix gets $1.6mm in Series A
- Series A for Prognomix raises $4.1mm
- GE buys Abbott's POC, diagnostics units for $8bn; withdrawn
- Dako to be acquired by equity firm
- Beckman Coulter loses bid to acquire Biosite
- Inverness Medical buys Biosite
- Quest buys HemoCue AB for $420mm
- Roche buys sequencing firm 454 Life Sciences for $155mm
Ask The Analyst
Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst
Your question has been successfully sent to the email address below and we will get back as soon as possible. firstname.lastname@example.org.
All fields are required.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.